Skip to content

Effective of Elman tablet on COVID-19 infection severity

Effective of Elman tablet on illness severity and length of hospital stay in the patients with COVID-19 infection

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200609047707N1
Enrollment
90
Registered
2020-06-24
Start date
2020-07-09
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients infected with Covid-19. Covid-19

Interventions

Intervention 1: First Intervention group (Elman Tablet): The tablet has an effective drug combination of L-cysteine, C3H7NO2S chemical formula and chemical structure of HS-CH2-CH (NH2) -COOH with L st

Sponsors

Esfarayen University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with COVID-19 disease based on PCR test The level of consciousness should be 15

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Connect the patient to the ventilator Low blood pressure at the beginning of the study (below 80/12) Has a history of gastrointestinal bleeding or active bleeding in the body Patients with immunodeficiency (under chemotherapy, organ transplantation and bone marrow transplantation, and patients with autoimmune diseases)

Design outcomes

Primary

MeasureTime frame
Illness severity. Timepoint: Every 12 hours for six day. Method of measurement: Using the checklist.

Secondary

MeasureTime frame
Length of hospital stay. Timepoint: It is controlled daily. Method of measurement: Calculate the number of days hospitalized within the corona ward.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Javad Hosseini

Esfarayen University of Medical Sciences

S.j.hoseini2016@gmail.com0098 5831550000- 602

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026